LY 156735

Drug Profile

LY 156735

Alternative Names: LY156,735; PD 6735; TIK-301

Latest Information Update: 26 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Tikvah Therapeutics
  • Class Sleep disorder therapies; Small molecules; Tryptamines
  • Mechanism of Action Melatonin receptor agonists; Serotonin 2C receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Sleep disorders

Most Recent Events

  • 25 Nov 2005 Data presented at the 18th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2005) have been added to the adverse events and Anxiety disorders therapeutic trials sections
  • 28 May 2004 LY 156735 has received orphan drug status for the treatment of circadian sleep disorders in totally blind individuals in the US
  • 24 May 2004 Data from a media release have been added to the Anxiety disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top